Xintela (XINT) Q1 2025 earnings summary

Executive summary

• Xintela reported Q1 2025 income of TSEK 140, with a loss before tax of TSEK 10,427, and loss per share of SEK 0.02, similar to the prior year.

• XSTEM showed excellent 18-month safety and efficacy results in osteoarthritis, with significant improvements in pain, function, and bone structure, and a trend toward halting cartilage breakdown.

• A collaboration and license agreement was signed with EQGen Biomedical for EQSTEM, granting global rights for veterinary musculoskeletal indications and providing upfront and milestone payments to Xintela.

• The patent portfolio was further strengthened with new grants and expanded geographic coverage, including key markets for XSTEM and EQSTEM.

Financial highlights

• Group operating loss for Q1 2025 was TSEK -10,094, improved from -10,802 year-over-year.

• Research and development costs were TSEK -7,299, down from -8,350 year-over-year.

• Cash and cash equivalents at March 31, 2025, were TSEK 6,398, compared to TSEK 10,409 a year earlier.

• Cash flow for the period was TSEK -10,214, compared to TSEK 3,310 in Q1 2024.

• Parent company equity/assets ratio was 48% at quarter-end.

Outlook and guidance

• Final osteoarthritis study report for XSTEM is planned for September 2025, with the highest dose being evaluated up to 24 months.

• Xintela aims for GMP manufacturing operations to become self-sufficient and cash flow positive through external assignments.

• Financing for development projects is expected to come from collaborations, licensing, and CDMO activities, with additional capital raising as needed.